![Shlomo Yanai, Teva's president and chief executive, speaks to the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly Shlomo Yanai, Teva's president and chief executive, speaks to the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly](https://c8.alamy.com/comp/2D1NC3K/shlomo-yanai-tevas-president-and-chief-executive-speaks-to-the-media-during-a-news-conference-in-tel-aviv-july-27-2010-teva-pharmaceutical-industries-the-worlds-largest-generic-drugmaker-reported-higher-quarterly-net-profit-on-tuesday-boosted-by-sales-of-generic-medicines-and-its-own-branded-multiple-sclerosis-treatment-copaxone-reutersnir-elias-israel-tags-business-headshot-2D1NC3K.jpg)
Shlomo Yanai, Teva's president and chief executive, speaks to the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis
![PDF) European Women With Multiple Sclerosis Feel Unprepared and Uneducated About Family Planning and Their Ability to Have Children – How Do We Improve Patient Education? PDF) European Women With Multiple Sclerosis Feel Unprepared and Uneducated About Family Planning and Their Ability to Have Children – How Do We Improve Patient Education?](https://i1.rgstatic.net/publication/325770230_European_Women_With_Multiple_Sclerosis_Feel_Unprepared_and_Uneducated_About_Family_Planning_and_Their_Ability_to_Have_Children_-_How_Do_We_Improve_Patient_Education/links/5b230b3fa6fdcc697464ee0b/largepreview.png)
PDF) European Women With Multiple Sclerosis Feel Unprepared and Uneducated About Family Planning and Their Ability to Have Children – How Do We Improve Patient Education?
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
![Two decades of glatiramer acetate: From initial discovery to the current development of generics - Journal of the Neurological Sciences Two decades of glatiramer acetate: From initial discovery to the current development of generics - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2118945372/2087083711/gr1.jpg)
Two decades of glatiramer acetate: From initial discovery to the current development of generics - Journal of the Neurological Sciences
![Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1550072420/K%C3%A5re_Schultz.jpg/K%C3%A5re_Schultz.jpg?VersionId=AkAld2.fqNUOre49lDIi3.nl41ZccSpR)
Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma
![PDF) A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis PDF) A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis](https://i1.rgstatic.net/publication/317319332_A_pharmacogenetic_signature_of_high_response_to_Copaxone_in_late-phase_clinical-trial_cohorts_of_multiple_sclerosis/links/595fdb48aca2728c118b62bc/largepreview.png)
PDF) A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
![Russia approves three-times-a-week Copaxone 40 mg/ml for treatment of RRMS - Pharmaceutical Business review Russia approves three-times-a-week Copaxone 40 mg/ml for treatment of RRMS - Pharmaceutical Business review](http://image.digitalinsightresearch.in/uploads/imagelibrary/Archive/Main/Copaxone.jpg)